Search PubMed⌕ Search

Biomedical subjects

D Wheatley

Publications and source records attributed to D Wheatley.

At least 55 records · Page 3Linked to original sources
PubMed1985

A comparison of diltiazem and atenolol in angina.

Diltiazem was compared to atenolol in a double-blind trial involving 78 patients suffering from coronary heart disease. Following a 2 week control period, patients were randomly allocated to 6 weeks treatment with one or the other drug. The patients themselves made daily records of anginal attacks, trinitrate requirements, well-being and exercise tolerance. With both drugs there were highly significant reductions in the anginal attack rate and trinitrate requirements, and significant improvement on the other measures. However, there were no significant between drug differences. The incidence of side effects with diltiazem was very low and no patient had to omit treatment for this reason, although three patients did so on atenolol.

Adult↗
PubMed1985

Zopiclone: a non-benzodiazepine hypnotic. Controlled comparison to temazepam in insomnia.

Zopiclone, a non-benzodiazepine hypnotic, was compared with temazepam in the treatment of 36 patients suffering from insomnia; the trial period was two weeks, with cross-over of medications at one week and a randomised order of administration. There were highly significant improvements with both drugs, as compared to the control period in respect of: sleep latency, number of times waking during the night, and quality and duration of sleep. The incidence of side-effects was very low. No significant between-drug differences were found in respect to any of the assessment measures or of the incidence of side-effects.

Adult↗
PubMed1984

Azapropazone in arthritis: a long-term treatment.

A long-term open assessment of azapropazone (900 mg to 1200 mg daily) was carried out in 51 patients suffering from osteoarthritis for periods of up to 1 year. Of these patients, 70% completed 9 to 12 months of treatment. Clinical assessments were made before and during the study of pain on motion or weight bearing, night pain, functional activity, morning stiffness, doctor's overall assessment, patients' overall assessment, and details of side-effects recorded. There were statistically significant improvements in the mean rating scores for each of the clinical assessments and these became apparent at 1 month, maximal at 3 to 6 months and persisted at the same level to the end of the trial. There were no side-effects recorded at any period of the trial in 30 (59%) patients. When side-effects did occur they were mild in 12 (24%), moderate in 3 (6%) and severe in 6 (12%) patients. The most frequent side-effects were related to the gastro-intestinal tract and gastric pain occurred in 7 (14%) patients, whilst rash or eczema occurred in 4 (8%) patients. It was concluded that, for the patients in the trial, long-term treatment with azapropazone was a useful and effective procedure.

Adult↗
PubMed1984

Psychological stress and cardiovascular diseases.

Mental stress may directly influence coronary heart disease (CHD) and also a number of its etiologic risk factors. Research work carried out by the Psychopharmacology Research Group in the United Kingdom indicates that antianxiety drugs may have an application in the management of the stress factors influencing CHD. In one study there was a significant reduction in the glyceryl trinitrate requirements of patients treated with a tranquilizer, but this result was not confirmed in two other studies. However, out of a total of 77 patients treated with a placebo, there were five cases of myocardial infarction during the trial periods as compared to no such cases among 81 patients treated with the antianxiety drugs.

Anti-Anxiety Agents↗
PubMed1984

Trazodone: alternative dose regimens and sleep.

In a double-blind trial, 146 depressed patients were allocated at random to treatment with the same daily dose (100 mg to 150 mg) of trazodone administered either as divided doses twice daily or as a single dose at night. Over the trial period of 6 weeks there was a highly significant reduction in the mean Hamilton Depression Rating Scale scores in both treatment groups, with no significant differences between them. The patients completed 10 visual analogue scales concerned with their depressive symptomatology, sleep patterns and daytime sequelae. Significant improvement was recorded on all items in both groups, the only significant between-group difference being in relation to how tired the patient felt during the day, which was significantly better on night-time dosage at Weeks 1 and 2. The most significant finding of the study was in relation to the sleep questionnaires completed by the patients on awakening and again in the evening. Trazodone administered as a single dose at night or when given in twice daily divided dosage, improved sleep. During the first week this effect was significantly better for the single dose at night group. This early effect may be particularly useful in providing psychological encouragement to depressed patients at the onset of treatment.

Adolescent↗
PubMed1983

Studies in general practice with brotizolam.

Brotizolam (0.25 mg) was compared with placebo, and in a separate study, with nitrazepam (5.0 mg) in patients being treated for insomnia in general practice. Brotizolam (0.25 mg) and nitrazepam (5.0 mg) were equally effective and there was no evidence of residual effects the next day with either drug.

Adult↗
PubMed1982

Analgesic properties of fluproquazone.

Fluproquazone, a new analgesic, was compared to a dextropropoxyphene hydrochloride and paracetamol combination (Cosalgesic) in a single blind trial lasting for five days. The trial included cases of various soft-tissue lesions and osteoarthrosis. Treatment was given to 170 patients, 84 of whom received fluproquazone and 86 the combination analgesic. The patients themselves made daily records of the severity of pain on a 100 mm visual analogue scale and in both treatment groups there was highly significant relief of pain, but with no significant differences between them. However, the incidence of side-effects was significantly higher with dextropropoxyphene hydrochloride-paracetamol (30%) than with fluproquazone (9%).

Acetaminophen↗
PubMed1982

The value of anti-anxiety drugs in the management of cardiac disease.

In 3 double-blind randomized trials, clorazepate was compared to placebo in post-infarction and pre-infarction patients, and diazepam was compared to placebo added to verapamil. There was a significant reduction in trinitrate requirement in the first clorazepate study but not in the second nor in the third, although this has not yet been completed. Taking all 3 trials together, there were 5 cases of myocardial infarction in 63 patients treated with placebo but no cases in 64 patients treated with the anti-anxiety drugs (p less than 0.05). Relief of anxiety was accompanied by reduction in the anginal attack rate with both active and placebo medications. In further similar studies in hypertension, relief of anxiety was also accompanied by reduction in blood pressure. However, in a 4-way comparison between lorazepam, bendrofluazide, lorazepam plus bendrofluazide and placebo, mean normotensive levels were only achieved in patients treated with the combination of anti-anxiety and antihypertensive medication.

Anti-Anxiety Agents↗
PubMed1982

Clenbuterol ("Spiropent'): a long-acting bronchodilator.

Clenbuterol was compared to an aminophylline preparation in a double-blind crossover trial involving 47 patients with asthma and reversible airways obstruction. Following a 2-week control period, each drug was given for a 4-week period. The patients made daily records of the severity of symptoms and recorded PEFR morning and night. Both drugs produced a highly significant reduction in severity and duration of wheeze by day during the first 4 weeks, but only clenbuterol produced further significant reduction in these symptoms during the second 4 weeks. Only clenbuterol produced a significant reduction in the severity of wheeze at night. When clenbuterol was given first there was a significant increase in the mean PEFR both night and morning but no other significant changes with either drug at other periods. Combining the results from the two treatment groups showed a significant difference between them in favour of clenbuterol in respect of duration of daytime wheeze only (p less than 0.05).

Adolescent↗
PubMed1982

Buspirone: multicenter efficacy study.

The efficacy and safety of buspirone (Buspar), diazepam (Valium), and placebo were compared in a 3-week double-blind study of 131 patients with scores of at least 15 on the Hamilton Rating Scale for Anxiety. Active drugs were administered orally in 5-mg tablets to a maximum dose of 10 mg t.i.d. Buspirone was given to 43 patients, diazepam to 46 and placebo to 42. There was significant improvement in all three treatment groups at 1 and 2 weeks, with further significant improvement with both active drugs, but not with placebo, at 3 weeks. The incidence of side effects reported voluntarily by patients was similar with the two active drugs, but drowsiness was significantly more frequent with diazepam.

Adult↗